BIOTYPE, a project led by IMSTAR and certified in 2006 by the Pôle de Compétitivité MEDICEN of the Paris Region, has come to its term, after 30 months.

It involved six innovative SMEs, Sanofi Aventis a big Pharma and four academic labs CEA, Pasteur Institute, Armines and AssitancePublique-Hôpitaux de Paris, to develop new approaches in functional cellular screening and molecular profiling in predictive and tailored medicine, using as a demonstrator the prostate cancer pathologies at different stages.

After one PhD, six papers, fifteen presentations in world class conferences, but also the set-up of integrated platforms involving high-throughput and high-content multiplex phenotyping characterization, it has proved to be fully sucessful in paving the way to clinical applications.